Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats.

Accelerated bone loss leading to osteopenia, osteoporosis, and bone fracture is a major health problem that is increasingly common in human immunodeficiency virus (HIV)-infected patients. The underlying pathogenesis is unclear but occurs in both treatment naïve and individuals receiving antiretroviral therapies. We developed an HIV-1 transgenic rat that exhibits many key features of HIV disease including HIV-1-induced changes in bone mineral density (BMD). A key determinant in the rate of bone loss is the differentiation of osteoclasts, the cells responsible for bone resorption. We found HIV-1 transgenic osteoclast precursors (OCP) express higher levels of suppressor of cytokine signaling-1 (SOCS-1) and TNF receptor-associated factor 6 (TRAF6) and are resistant to interferon-gamma (IFN-γ) mediated suppression of osteoclast differentiation. Our data suggest that dysregulated SOCS-1 expression by HIV-1 transgenic OCP promotes osteoclastogenesis leading to the accelerated bone loss observed in this animal model. We propose that elevated SOCS-1 expression in OCP antagonizes the inhibitory effects of IFN-γ and enhances receptor activator of NF-kB ligand (RANKL) signaling that drives osteoclast differentiation and activation. Understanding the molecular mechanisms of HIV-associated BMD changes has the potential to detect and treat bone metabolism disturbances early and improve the quality of life in patients.

[1]  S. Emery,et al.  Bone turnover markers in HIV disease. , 2011, AIDS reviews.

[2]  Kosaku Kurata,et al.  Evidence for osteocyte regulation of bone homeostasis through RANKL expression , 2011, Nature Medicine.

[3]  Jinhu Xiong,et al.  Matrix-embedded cells control osteoclast formation , 2011, Nature Medicine.

[4]  K. Buchacz,et al.  Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Joseph L. Goulet,et al.  Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans , 2011, PloS one.

[6]  I. Ofotokun,et al.  HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture , 2010, Current opinion in endocrinology, diabetes, and obesity.

[7]  E. McCloskey,et al.  HIV and bone disease. , 2010, Archives of biochemistry and biophysics.

[8]  Jeannie S. Huang,et al.  Bone disease in HIV infection: a practical review and recommendations for HIV care providers. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  I. Ofotokun,et al.  Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats , 2010, Proceedings of the National Academy of Sciences.

[10]  S. Hammer,et al.  Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. , 2010, The Journal of clinical endocrinology and metabolism.

[11]  R. Fajardo,et al.  Inhibition of RANK Expression and Osteoclastogenesis by TLRs and IFN-γ in Human Osteoclast Precursors1 , 2009, The Journal of Immunology.

[12]  Lionel B Ivashkiv,et al.  Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. , 2009, Immunity.

[13]  S. Deeks.  Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[14]  R. Redfield,et al.  Increased expression of suppressor of cytokine signaling-1 (SOCS-1): A mechanism for dysregulated T helper-1 responses in HIV-1 disease. , 2009, Virology.

[15]  T. Brown,et al.  Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. , 2008, The Journal of clinical endocrinology and metabolism.

[16]  H. Takayanagi,et al.  The dynamic interplay between osteoclasts and the immune system. , 2008, Archives of biochemistry and biophysics.

[17]  R. Pacifici,et al.  T Cells: Unexpected Players in the Bone Loss Induced by Estrogen Deficiency and in Basal Bone Homeostasis , 2007, Annals of the New York Academy of Sciences.

[18]  F. Chiodo,et al.  RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV‐1‐positive men , 2007, Journal of medical virology.

[19]  T. Brown,et al.  Response to Berg et al. 'Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review'. , 2007, AIDS.

[20]  I. Reid,et al.  Bone mineral density remains stable in HAART‐treated HIV‐infected men over 2 years , 2007, Clinical endocrinology.

[21]  S. Walmsley,et al.  Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study , 2007, Osteoporosis International.

[22]  Wei-Ping Qian,et al.  B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. , 2007, Blood.

[23]  M. Terauchi,et al.  IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation , 2007 .

[24]  T. Brown,et al.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.

[25]  D. Huso,et al.  HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation. , 2006, Virology.

[26]  S. Grinspoon,et al.  Longitudinal analysis of bone density in human immunodeficiency virus-infected women. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  Hiroshi Takayanagi,et al.  Interplay between interferon and other cytokine systems in bone metabolism , 2005, Immunological reviews.

[28]  E. Shane,et al.  Bone mass and mineral metabolism in HIV+ postmenopausal women , 2005, Osteoporosis International.

[29]  A. Yoshimura,et al.  Suppressors of Cytokine Signaling-1 and -3 Regulate Osteoclastogenesis in the Presence of Inflammatory Cytokines1 , 2005, The Journal of Immunology.

[30]  M. Reitz,et al.  HIV-1 transgenic rats develop T cell abnormalities. , 2004, Virology.

[31]  F. Chessa,et al.  Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[32]  C. Baudoin,et al.  BMD Is Reduced in HIV‐Infected Men Irrespective of Treatment , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  J. Laurence,et al.  HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-γ/RANKL Cross-talk* , 2003, Journal of Biological Chemistry.

[34]  K. Heeg,et al.  Triggering of Toll‐like receptors modulates IFN‐γ signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling , 2003, European journal of immunology.

[35]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[36]  K. Yarasheski,et al.  Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[38]  M. Kumegawa,et al.  Regulation of Receptor Activator of NF-κB Ligand-induced Osteoclastogenesis by Endogenous Interferon-β (INF-β) and Suppressors of Cytokine Signaling (SOCS) , 2002, The Journal of Biological Chemistry.

[39]  M. Reitz,et al.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. John,et al.  Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir , 2001, AIDS.

[41]  J. Eisman,et al.  Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy , 2001, AIDS.

[42]  A. Mukherjee,et al.  Tumor Necrosis Factor-α (TNF) Stimulates RANKL-induced Osteoclastogenesis via Coupling of TNF Type 1 Receptor and RANK Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[43]  Y.-P. Li,et al.  Interferon-γ Down-regulates Gene Expression of Cathepsin K in Osteoclasts and Inhibits Osteoclast Formation , 2001, Journal of dental research.

[44]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[45]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[46]  R. Fullilove,et al.  The Family to Family program: a structural intervention with implications for the prevention of HIV/AIDS and other community epidemics , 2000, AIDS.

[47]  K. Yarasheski,et al.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.

[48]  T. Miyata,et al.  Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.

[49]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[50]  T. Martin,et al.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.

[51]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[52]  R. Steinman,et al.  The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor* , 1998, The Journal of Biological Chemistry.

[53]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[54]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[56]  S. Ralston,et al.  Cytokine‐Induced Nitric Oxide Inhibits Bone Resorption by Inducing Apoptosis of Osteoclast Progenitors and Suppressing Osteoclast Activity , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[58]  N. Paton,et al.  Bone Mineral Density in Patients with Human Immunodeficiency Virus Infection , 1997, Calcified Tissue International.

[59]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[60]  R. Jilka,et al.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.

[61]  S. Lowry,et al.  Tumor necrosis factor-α , 1991 .

[62]  G. Roodman,et al.  Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. , 1986, Journal of immunology.

[63]  M. Terauchi,et al.  IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. , 2007, The Journal of clinical investigation.

[64]  Teiji Wada,et al.  RANKL-RANK signaling in osteoclastogenesis and bone disease. , 2006, Trends in molecular medicine.

[65]  J. Laurence,et al.  HIV-1 Vpr enhances production of receptor of activated NF-κB ligand (RANKL) via potentiation of glucocorticoid receptor activity , 2004, Archives of Virology.

[66]  M. Kumegawa,et al.  Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. , 2002, The Journal of biological chemistry.

[67]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[68]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[69]  S. Manolagas.  Bone marrow, cytokines, and bone remodeling , 1995 .

[70]  M. Clerici,et al.  A TH1-->TH2 switch is a critical step in the etiology of HIV infection. , 1993, Immunology today.

[71]  D. Strait,et al.  Healthcare Systems , 1988, Symposium Record Policy Issues in Information and Communication Technologies in Medical Applications.